#GivingTuesdayNow on May 5, 2020, is a global day of generosity and unity, a day to come together and give back in response to the unprecedented need caused by COVID-19. AE Alliance will participate in Giving Tuesday Now and launch the AEA Research Network with webinars by Dr. Sean Pittock (Mayo Clinic) and Dr. Stanley Naides (EuroImmun).
COVID-19 has brought uncertainty, isolation, pain, and loss to our lives and has literally changed the way we live. As we adapt to this new reality, we have also seen positive developments that bring hope. We see a fierce, urgent, and collaborative response of pharmaceutical companies, researchers, and other stakeholders to explore treatments and develop vaccines to combat the Coronavirus. This effort shows we can achieve a lot by working together on a common goal. AEA wants to build on this momentum by investing heavily in AE research. Research is key to understanding the disease process and to developing specific treatments and eventually, a cure for AE.
We know the challenges that come with rare disease research, often come down to small numbers; small patient population, small number of researchers, and limited funding. But there is hope. More and more pharmaceutical companies are expressing an interest in AE. AE Alliance has a broad and international base of physicians and researchers on both their Medical Advisory Board and Clinicians Network. And by uniting patients, survivors, caregivers and others interested in AE, in the Research Network, we can work across the board to push AE Research forward.
By joining the Research Network, you will not only invest in research but become an active part of it. Over the coming week, you will learn more about AE research. You will learn about its challenges and possibilities and how you are in a unique position to drive research forward.
Together, we can change the course of AE.
Can’t wait to get started? Join the Research Network today, click here to register.
Listen to Dr. Heather Van Mater, as she talks about advancing AE Research in light of COVID-19.